background: The aim of this study was to evaluate the impact of post-operative oral contraceptives (OCs) use on the rate of recurrence after laparoscopic excision of ovarian endometrioma.
Introduction
Ovarian endometrioma accounts for 55% of reported endometriosis cases (Jenkins et al., 1986) . Most cases are treated conservatively since endometrioma is commonly diagnosed in women of reproductive age (Giudice and Kao, 2004) . Currently, laparoscopic excision is considered to be the 'gold standard' for the conservative treatment of endometrioma (Beretta et al., 1998) and the European Society of Human Reproduction and Embryology (ESHRE) guidelines recommend that laparoscopic ovarian cystectomy can be considered if an ovarian endometrioma .3 cm in diameter is present (to confirm the diagnosis histologically) and for the purpose of reducing the risk of infection, improving access to follicles and possibly improving ovarian response (Kennedy et al., 2005) .
However, a frustrating aspect of laparoscopic excision of endometrioma is the disease recurrence after surgery. We have previously reported as high as 30.4% recurrence within 2 years after surgery (Koga et al., 2006) . Although the definition of recurrence can vary, other recent studies also indicate a 30% recurrence rate after 3-5 years of follow-up (Kikuchi et al., 2006; Liu et al., 2007) , which is higher than previously believed.
Whereas laparoscopic excision is known to improve fertility (Chapron et al., 2002) , recurrence and repeated surgery can cause significant ovarian damage, thus reducing future reproductive performance. Given that the majority of women who undergo this operation seek pregnancy in the future, a dilemma arises when a physician plans laparoscopy, with the expectation that fertility should improve but with concerns that future recurrence can place fertility at risk. It is therefore crucial to prevent recurrence after laparoscopic excision in order to maintain 'improved' fertility for long as possible.
Despite the necessity, a gold standard treatment modality of preventing recurrence does not yet exist. According to ESHRE guidelines (Kennedy et al., 2005 ) and the Cochrane library (Yap et al., 2004) , post-operative hormonal treatment does not significantly reduce symptoms at 12 or 24 months, and has no effect on disease recurrence. However, the Cochrane library added 'there is insufficient evidence to conclude that hormonal treatment in association with surgery is associated with a significant benefit' (Yap et al., 2004) . As a result, it has remained controversial as to whether post-operative medical treatment or different drug treatments can reduce disease recurrence.
Previously, we analyzed risk factors that are associated with the recurrence of endometrioma after laparoscopic excision and identified post-operative pregnancy as a favorable prognostic factor (Koga et al., 2006) . The benefit of pregnancy on recurrence has also been observed in other reports (Busacca et al., 2006; Porpora et al., 2008) . This prompted us to hypothesize that post-operative administration of oral contraceptive (OC) pills, which inhibit ovulation and create a pregnancy-like hormonal condition, may reduce the incidence of endometriosis recurrence. When we completed our previous study, only one randomized controlled trial had attempted to evaluate the efficacy of post-operative OC use for reducing recurrence (Muzii et al., 2000) . However, the duration of OC administration in this study (Muzii et al., 2000) was limited to 6 months, consequently the long-term effect of OC on recurrence has been remained unclear.
Given that OC may reduce the recurrence after laparoscopic endometrioma excision, in May 2005, our clinic introduced a 'postoperative OC recommendation' for patients who underwent a laparoscopic excision of endometrioma. That is, at the time of the operation, we provided each patient with information about OC, and known and possible benefits and risks and let her decide whether or not to take OC. In this study, we conducted two analyses, a 'retrospective cohort study' and a 'before -after study'. In the retrospective cohort study, we compared recurrences between OC users and non-users to evaluate the 'effect' of OC use on endometriosis recurrences. On the other hand, the before -after study is a historical study which compares recurrences between before and after the introduction of the 'postoperative OC recommendation' in a clinical setting to define the efficiency of the 'post-operative OC recommendation' for the overall population.
Materials and Methods

Subjects
This investigation consists of two studies (i) a retrospective cohort study and (ii) a before-after study. For the retrospective cohort study, a total of 137 patients who underwent a laparoscopic excision of ovarian endometrioma performed at the University of Tokyo Hospital between May 2005 and August 2006 were enrolled. Of the 137 subjects originally enrolled, a total of 87 women who had a minimum of 24 months of postoperative follow-up were studied. The clinical characteristics of these patients are summarized in Table I .
For the before-after study, we included another 332 patients who underwent the same procedures in the same hospital but between January 1995 and December 2002 (before the introduction of 'postoperative OC recommendation'). Of the 332 subjects originally enrolled, a total of 224 who had a minimum of 24 months of post-operative follow-up were compared with the above-mentioned 87 patients (after the introduction of 'post-operative OC recommendation').
We confirmed that there was no significant difference in clinical characteristics between patients who were lost to follow-up and who were not, both before and after the introduction of the 'post-operative OC recommendation'. Institutional Review Board approval was not requested because laparoscopic excision is a standard procedure for the treatment of ovarian endometrioma. All patients gave written informed consent before surgery.
Surgery and the 'post-operative OC recommendation'
The method of laparoscopic excision of ovarian endometrioma was performed as previously described (Koga et al., 2006) . Briefly, after the ovary was freed from any adhesion, the capsule of the cyst was completely stripped away from the normal ovarian tissue. Endometriotic peritoneal implants were excised with scissors or coagulated with bipolar electro coagulation.
In May 2005, we introduced the 'post-operative OC recommendation' for patients treated with laparoscopic excision of endometrioma, who were under the age of 40 and not seeking pregnancy. At the time of the laparoscopy, every patient was routinely provided with the following information about OC: (i) known side-effects (nausea etc.) and risks (thrombosis etc.) and their likelihoods, (ii) known benefits supported by conclusive evidence (reducing pain etc.) and (iii) the possible benefits of reducing or delaying recurrence, not supported by conclusive data but the theoretical explanations. We also provided the recurrence rate and risk factors that we analyzed in our previous study (Koga et al., 2006) . The decision to take OC was left up to the individual women. Women who chose to take OC, were given a cyclic, monophasic OC containing ethinyl-estradiol (0.035 mg) and norethisterone (1.0 mg) (Ortho-M 21w, Mochida, Tokyo, Japan), starting in Days 1 -5 of the first menstrual cycle after the laparoscopy. Post-operative OCs reduce endometrioma recurrence
Post-operative follow-up and diagnosis of recurrence
Post-operative follow-up was performed by transvaginal ultrasonography. The initial check up was conducted on Day 4 and Day 30 after the operation, to exclude residual cysts. Patients were then followed-up every 3 months for 24 months following the laparoscopy. The diagnosis of endometrioma recurrence was made as described in our previous study (Koga et al., 2006) . Briefly, a recurrence was defined as the presence of cysts with a typical aspect detected by transvaginal ultrasonography (Exacoustos et al., 2003) more than 2 cm in diameter. The diagnosis of recurrence endometrioma was made when the cyst was indistinguishable from a corpus luteum cyst or intraovarian hematoma, and the cyst had not disappeared after several successive examinations. Recurrence was defined by the diagnosis of ovarian endometrioma at anytime within 24 months. Pain recurrence was defined as requiring analgesia at least once a month for dysmenorrhea or chronic pelvic pain at 24 months after the laparoscopy.
Statistical analysis
For the retrospective cohort study, we compared patients' characteristics between OC users and non-users by Mann -Whitney U-test and Fisher's exact test. Relative risk of OC use for endometrioma recurrence was calculated. Ten variables: age, presence of infertility, pain, previous medical treatment of endometriosis, previous surgery for ovarian endometrioma, the diameter of the largest cyst, unilateral or bilateral involvement, revised American Society of Reproductive Medicine (revised ASRM) score, post-operative OC use and post-operative pregnancy were evaluated to assess their independent effects on the recurrence rate using univariate analysis followed by a step-wise selection and logistic regression analysis.
For the before-after study, we used the Mann -Whitney U-test and Fisher's exact test to compare patients' characteristics between patients who underwent laparoscopy before and after the introduction of the 'post-operative OC recommendation'. The relative risk of the introduction of 'post-operative OC recommendation' for endometrioma recurrence was calculated.
Statistical analyses were performed by Statview for windows Ver. 5.0 (SAS Institute Inc., Cary, NC, USA). A P-value of ,0.05 was considered statistically significant.
Results
Retrospective cohort study Fig. 1 shows the flowchart of the 87 patients who underwent laparoscopic excision of endmetrioma after May 2005. All received the 'postoperative OC recommendation'. Of the 87 patients, 48 started to take OCs, but 39 did not. The reasons for not commencing OC were seeking pregnancy (n ¼ 25) and age over 40 (n ¼ 6) although 8 women chose not to take OC without a particular reason. Of the 48 patients who had started OC, 34 continued OC for the entire study period (24 months), whereas 14 discontinued. The reasons for discontinuing OC were desire for pregnancy (n ¼ 5), and side effects (n ¼ 9). This group suffered minor side effects e.g. headache and nausea; major complications such as thrombosis did not occur. The mean length of OC taken in this group was 9.7 + 6.1 months.
Endometrioma recurrence was detected in 20 out of 87 subjects (23.0%) in all study groups. The mean diameter of the recurrent cyst at diagnosis was 33.1 + 12.0 (SD) mm. Among patients who had recurrence, one underwent second-line surgery due to the large size of the recurrent cyst.
We then calculated recurrence rates with patients who used OC for the entire study period (entire period OC group), patients who discontinued OC (discontinuous OC group) and patients who never used OC (never OC group). The recurrence rates were 2.9% (1/ 34), 14.3% (2/14) and 43.5% (17/39) for the entire period OC, discontinuous OC and never OC groups, respectively.
We then combined the discontinuous OC group and never OC group together ('others') and compared that with the entire period OC group ('entire period OC group'). Table II shows the comparison of patients' characteristics between these two groups. Age, percentages of patients who have pain, previous medical treatment of endometriosis, previous surgery of ovarian endometrioma, the diameters of the largest cyst at laparoscopy, the percentage of patients who had bilateral involvement and the revised ASRM scores were not significantly different between groups. The percentage of patients who were infertile and patients who achieved pregnancy in the postoperative period were significantly lower in the 'entire period OC group' (P , 0.05 for both).
We then compared the recurrence rate between the groups. The recurrence rate in the 'entire period OC group' was significantly lower than in the 'others' (2.9 versus 35.8%, relative risk 0.082, 95% CI 0.012-0.58, P , 0.001). This indicates that taking OC without cessation reduces the risk of endometrioma recurrence by a factor of 12.
In order to confirm whether post-operative OC use is independently associated with the lower recurrence rate, we further performed univariate analysis followed by logistic regression analysis A total of 87 patients were followed up for 24 months. Of the 87 patients, 48 started to take OCs, but 39 did not. Of the 48 patients who had started OC, 34 continued OC for the entire study period (24 months), whereas 14 discontinued. Recurrence was detected in 20 out of 87 subjects (23.0%) in all study groups. To determine the effect of OC use on recurrence, we compared recurrence rates with patients who used OC for the entire study period (entire period OC group), patients who discontinued OC use (discontinuous OC group) and patients who never used OC (never OC group). The recurrence rate was 2.9% (1/34), 14.3% (2/14) and 43.5% (17/39) in the entire period OC, discontinuous OC and never OC groups, respectively. (Table III) . Ten variables were evaluated by univariate analysis and three variables (age, revised ASRM score and post-operative use of OC) were selected for logistic regression analysis by a forward stepwise variable selection. Post-operative use of OC was determined as an independent variable which is associated with lower recurrence (OR 0.054, 95% CI 0.007-0.429, P , 0.001). A higher revised ASRM score was significantly associated with higher recurrence (OR 1.018, 95% CI 1.003 -1.034, P , 0.01). Neither infertility nor post-operative pregnancy influenced the rate of recurrence.
Before-after study
To evaluate the impact of the 'post-operative OC recommendation' on the endometrioma recurrence rate and pain recurrence rate in the overall population who underwent laparoscopic excision, we performed a historical study, the before-after study. Among patients who had a minimum of 24 months of post-operative follow-up, patients who were over the age of 40 and/or were infertile were excluded since these patients would not take OC regardless the recommendation. In total, 133 received laparoscopy before the introduction of 'post-operative OC recommendation' and 70 underwent laparoscopy after the introduction of the 'post-operative OC recommendation'. As indicated in Table IV , clinical characteristics of both groups were not different except for the patient's age. Among patients who received laparoscopy before the introduction of the 'OC recommendation', 15.8% actually used post-operative medical therapy including OC, GnRH analogue etc., whereas among patients who underwent laparoscopy after the introduction of 'OC recommendation', 78.6% started post-operative medical therapy, and most of the cases in this group was OC.
We then compared the recurrence rate between the groups. The overall endometrioma recurrence rate in patients who underwent laparoscopy after the introduction of the 'post-operative OC recommendation' was significantly lower than that in patients who received laparoscopy before the 'post-operative OC recommendation' (18.6 versus 33.1%, relative risk 0.56, 95% CI 0.32 -0.97, P , 0.05). As for pain recurrence, the recurrence rate was not significantly different between the groups (58.7 versus 53.1% in before versus after the introduction of the 'post-operative OC recommendation', relative risk 0.90, 95% CI 0.62 -1.31, P ¼ 0.6739).
Discussion
In this study, we demonstrated the 'effect' of post-operative OC use on the recurrence of ovarian endometrioma following laparoscopic excision in a retrospective cohort study. Furthermore, we showed the 'efficiency' of our intervention; the introduction of the 'postoperative OC recommendation', for reducing the overall recurrence rate in a before -after study.
In the retrospective cohort study, we demonstrated that postoperative OC use significantly reduces the recurrence of ovarian endometrioma within 24 months following laparoscopic excision. The recurrence rate after surgery in patients who used OC for the entire study period (24 months), in patients who discontinued OC and in patients who never used OC was 2.9, 14.3 and 43.5%, respectively. The relative risk of recurrence was 0.082 in patients who used OC for the entire study period compared with patients who did not, in other words, patients who took post-operative OC without cessation were12 times less likely to have recurrence. We further showed that post-operative use of OC is an independent variable Post-operative OCs reduce endometrioma recurrence that is associated with lower recurrence. Subsequent to our previous study (Koga et al., 2006) and commencement of the 'post-operative OC recommendation' in our clinic in 2005, two studies have been conducted to investigate the efficacy of post-operative OC in preventing endometrioma recurrence following laparoscopic excision. Vercellini et al. (2008a, b) evaluated the recurrence within 36 months after excision and reported that 94% were recurrence-free in the always OC users compared with 51% in the never users, with an incidence rate ratio of 0.10. Furthermore, in a study comparing cyclic and continuous OC use versus non-use, the recurrence rates within 24 months were 14.7, 8.2 and 29%, respectively (Seracchioli et al., 2008) . Our current results corroborate with these observations and strongly support the proposal that post-operative OC administration reduces the endometrioma recurrence rate after laparoscopic excision. In addition to the 'effect' of post-operative OC use, we further demonstrated the 'efficiency' of the introduction of the 'postoperative OC recommendation' for reducing the endometrioma recurrence rate in the overall population who underwent laparoscopic excision, as demonstrated by the before -after study. The overall recurrence rate declined significantly from before to after the introduction of 'post-operative OC recommendation'. This is a unique observation that showed the impact of 'post-operative OC recommendation' in a daily clinical context. As a consequence of informing patients of the 'possible' benefits of OC in preventing recurrence and leaving the decision whether to take and continue OC to individuals, not many patients chose OC. However, the introduction of a 'post-operative OC recommendation' significantly contributed to the reduction of recurrence among the overall population who underwent laparoscopic excision. This encourages us to continue the 'postoperative OC recommendation' with further emphasis of its benefit in reducing endometrioma recurrence.
In contrast to the efficiency of the OC recommendation for reducing endometrioma recurrence, the intervention did not decrease pain recurrence. One explanation would be that the pain does not necessarily reflect the presence of endometriosis. It is also possible that our pain evaluation did not detect a subtle change of pain severity because it was not quantitative. Further studies are needed to determine the effect of OC on pain recurrence.
This study also suggests that OC can provide a better option in terms of safety and tolerability. Despite the small study group, no patients developed major complications and all side effects reported were minor, which is consistent with a previous report which used OC for dysmenorrhea (Harada et al., 2008) . Moreover, although the recommendation was not absolute, most women continued OC, indicating a good tolerability that yielded high compliance. This is in contrast to other hormonal drugs for endometriosis such as GnRH analogue and danazol, which are known to cause various side effects (Vercellini et al., 2008a, b) .
The mechanism by which OC reduces endometrioma recurrence has not been elucidated. Previously, we found that post-operative pregnancy was associated with a low recurrence rate (Koga et al., 2006) , and consequently we hypothesized that pregnancy or a pregnancy-mimicking hormonal condition may reduce the risk of recurrence. Indeed, several epidemiological studies have shown that OC use reduces the risk of endometriosis development (Vercellini et al., 1993; Vessey et al., 1993; Missmer et al., 2004) . One possible explanation is the effect of OC on the eutopic endometrium. OC intake has been reported to increase apoptosis and decrease cell proliferation in the eutopic endometrium (Meresman et al., 2002) , which could result in lowering de novo endometriosis development. It is also possible that OC may decrease the risk of endometrioma development by inhibiting ovulation since ovarian endometrioma can develop from ovarian follicles (Jain and Dalton, 1999) and corpus luteum (Vercellini et al., 2009) . Additionally, OC intake diminishes the amount of retrograde menstruation and reduces the chance of recurrence in the same manner as endometrial ablation can prevent endometriosis recurrence (Bulletti et al., 2001; Osuga, 2008) . If this is the case, it would be interesting to compare the effect of OC between cyclic and continuous administration since the latter yields less frequent bleeding. Intriguingly, Seracchioli et al. (2008) addressed this point and reported that the recurrence rate was slightly lower in continuous OC users than in cyclic users, although the difference was not statistically significant. Further studies will be needed to confirm a benefit of continuous OC.
Our study arouses debate in regard to the benefits of OC administration; whether it 'prevents' recurrence or 'delays' it. The first study to evaluate the efficacy of post-operative OC demonstrated that using OC for a period of 6 months reduced the recurrence rate at 12 months, compared with controls, but then by 24 months this benefit was eroded and recurrence was similar to non-user controls (Muzii et al., 2000) . Consequently this group concluded that postoperative OC does not affect the long-term recurrence rate but achieves a delay in recurrence. Focusing on the disease recurrence after the cessation of OC, this observation seems consistent with ours and others (Vercellini et al., 2008a, b) , that OC users have an extremely small chance of recurrence (2.9% in our study, 6% in others) whereas patients who discontinued OC were at higher risk. These findings suggest that OC administration may only 'delay' the chance of recurrence rather than 'prevent'. From the clinical point of view, however, this 'delay' provides a significant benefit especially for patients who seek pregnancy several years after the laparoscopy. There are several limitations in the current study. Firstly, the numbers of patients in both the retrospective cohort study and the before -after study were not sufficient enough to generalize the results to the general population, although the difference in each study was statistically significant. Secondly, since the retrospective cohort study was designed in a clinical context rather than in an experimental context, the allocation of subjects to OC groups was not random but based on patient preference. Therefore, the result might be affected by selection bias. This may explain why the magnitude of OC-use benefit in our study was comparable with the one designed in a clinical context (Vercellini et al., 2008a, b) , but was slightly different from the one conducted in more experimental context (Seracchioli et al., 2008) . Lastly, we cannot exclude the presence of confounding factors in our before-after study, such as surgical technique and surgeons' experience, although we tried to minimize them. Further studies will be necessary to overcome these limitations.
Several questions remain unanswered. Firstly, how long should patients continue using OC? Given that most of studies set the OC administration period at ,3 years, it will be interesting to see whether OC can yield 'preventive' effects if the period of treatment is prolonged. Secondly, up to what age should OC is recommended? In the current study, we did not offer 'post-operative OC recommendation' for patients over the age of 40, since OC is considered to be relatively contraindicated for women over the age 40, in regard to promoting thrombotic disease (1981). However, given that an increasing number of women seek pregnancy in their early 40s and that the presence of endometriosis in the 40s has a high risk of cancer development (Kobayashi et al., 2008) , we must weigh the benefits of OC in preventing the recurrence against the possible adverse effects of OC. Further evidence is necessary to evaluate both efficacy and safety.
In summary, this study demonstrates that post-operative OC use reduces the risk of ovarian endometrioma recurrence after laparoscopic excision. Having this information will help gynecologists and patients plan pre-and post-operative management appropriately to prevent recurrence and consequently to maintain fertility for long as possible.
